Member Info for Brand

It's much more important for the update to be good, rather than quick.

Something else to consider, a primary endpoint of time to release from hospital, across 17 countries, in the delta wave, with beds and care at extreme levels of demand and a changing and no doubt uneven SOC between jurisdictions.

I could be wrong, but believe I remember a comment from RM along the lines of 'we started to see vaccinated patients that fit the criteria, so we took the decision to include them as well' (paraphrasing).

Could it really be that simple that if you strip out the vaxed patients the difference is significant?

NDN, Costs - what about Ray tho? Is he our knight in shining armour?

Pretty incredible to bring on someone like that and then release what they did isn't it?

Anyone here that was invested before Monday will no doubt remember Fridays news of pharma heavy hitter Ray Jordan taking on synairgen as his first client for his newly minted PR agency...

https://www.prweek.com/article/1741002/pharma-comms-veteran-ray-jordan-launches-consultancy-putnam-insights

So, an open question for the board:

The last hurrah of SNG before they saw the data and then released the exceptionally poor RNS, never to be heard from again?

OR

Our Winston Wolf, here to clean up the s#!t show and save the day?

OR

Something else entirely?

Well here I am in general agreement with NDN/Andybe, doesn't disaster make strange bedfellows!

Some thoughts...

Paramount is the safety data, INF use has a long and complicated history and from up close experience I know the side effects from systemic administration can be downright horrible - this shaped medical opinion after its introduction as a 'wonder drug' in the 90s and was a huge hurdle to overcome. Further, the 'timing of SNG001' issue also looks to be put to bed, with the drug proving safe in 'late' administration to hospitalized patients

There is a huge amount of data regarding SNG001 vs Covid, almost all of it positive between P1/2/3 in hospitalized patients and ACTIV2P2 and the UK home trial. Given the FDAs involvement in deciding the parameters of sprinter and NIHs intensive study in ACTIV, will they let RM and team 'Pfizer up the data' and consider EUA across the full body of work? There are literally 1000s of people dying everyday from Covid - 40% reduction of severe disease or death above and beyond the much improved SOC sounds pretty damn good.

Ray Jordan - last hurrah of bullish SNG and never to be seen again, or Winston Wolf, coming to save the day? TBC I guess

ACTIV 2P3 - this is what it's all about now. Looking at SAB, they got a 60m USD grant and I believe a conditional pre-order based on progression to A2P3, will SNG get similar? If so where would the SP be then?

RM - hard to make any judgement w/o knowing the details, but obviously he's the boss so the responsibility lies with him. Gonna need to be a pretty stellar performance when he finally makes an appearance. I think it's right to let the dust settle and let the data be analysed and then come out swinging.

There's more.. long covid, Poly increasing/decreasing (I think increasing but we should find out soon enough) and of course SNG001's ability Vs Influenza, RSV etc.

Monday was an almighty kick in the nuts, it wasn't a fatal blow and this isn't over yet. Maybe I'm hopelessly optimistic, but we know it works. Here for the long haul.

PS - NDN surely we would need to share that Nobel prize no? ;-)

Tommy,

I’d love to be able to combine p2 and p3 but they had completely different SOC. so I’d guess any readout is meaningless?

A fair point, but that is the case for everything w covid, it's a moving target with a constanttly changing SOC. We know Pfizer removed a huge amount of patients (vaxed etc) from the Paxlovid data and the Merck drugs has all sorts of issues + we are still seeing the use of drugs shown to have minimal effect Vs Omicron.

I don't know enough about how EUA, FDA approvals work to give an educated view on what can/can't happen, but I think it's fair to say that it's definitely not business as usual. There has been a very significant amount of positive data produced over the last 2 years on SNG inhaled INFb Vs Covid and most importantly a huge amount of safety data. I'm holding on tight.

Thank you Richlist, much appreciated. I am very keen to see what the team at SNG can do with the combined data and insights gained over the last two years.

Any of the clever folks on this board want to try and combine the ‘Progression to severe disease or death within 35 days’ for P2 &P3 and share the data with us?

Still here, still holding.

Just an alternative theory - all of the military build-up, rhetoric etc is to build a negotiating position to consolidate and cement the gains of Donbass and Crimea.

And as far as SNG goes, in the very - incredibly - unlikely event of a full scale invasion and P3 results on the same day, maybe the initial spike in sp isn't as high as it could be, but makes no difference to the company and its prospects beyond that.

So I had a little peak back at the board on the day this dodgy article dropped and came across the below, posted less than 5 minutes after the article appeared...

It's quite detailed and well written and I can't help but ask myself if this poster had prior knowledge of the article before it was published. Expect if you found the admin of this account, you'd probably also find the source of the dodgy article imho...

'RE: sng03 Dec 2021 16:31
It’s very interesting to see the quotes professor Eleanor Fish of the university of Toronto who was the one casting doubt over the use of inhaled interferon beta.

A quick google search of Fish, who is British and now works in Toronto, has a team working on interferon alpha for the treatment of Covid.

Hmm, the cynical side of me would suggest that she wants to try and put down the competition because she knows that once the Interferon beta SNG001 is approved = the end of her studies in interferon alpha.

The inflammation markers will have been checked in the ACTIV 2 Phase 2 trial when the NIH team was checking the safety of SNG001.
In fact, if one recalls, there was a long gap between Dr. Castro saying the Interferons were through, we just have to check the safety data and then actually going through to Phase 3.

It’s highly likely that the NIH was checking the inflammatory markers during the Phase 2 trial.

Needless to say it’s also highly likely that other professors (potentially from Pfizer and other big pharma companies) may come out and make similar ‘suggestions’.

Competitors do not want SNG001 to succeed. But it will. Hence why there was no scope to cut the trial early and unblind the results, the team knows everything must be air tight because the scrutiny will be on next level.'

I've asked the author and Clinical Trials Arena if they can shed any light on the situation via twitter, still awaiting reply

https://twitter.com/onebrandondavis/status/1494669546619392009?t=keOSZRAD_bSYDKZZ9EKJLw&s=19

This is a no nonsense, straight to the point, call to arms - YLTSI

Once SNG001 is approved for EUA and in use, it will rightfully undergo a massive number of trials, some of which will be home runs, others maybe misses.

But the fact is some 25yrs after synthetic Interferons were first approved for use in humans, a novel, minimal side effect delivery method will be in play.

Covid is just the foot in the door...

https://www.researchgate.net/publication/358585404_Interferon-b_Activity_Is_Affected_by_S100B_Protein

Full study behind a paywall...

'Interferon-ß (IFN-ß) is a pleiotropic cytokine secreted in response to various pathological conditions and is clinically used for therapy of multiple sclerosis. Its application for treatment of cancer, infections and pulmonary diseases is limited by incomplete understanding of regulatory mechanisms of its functioning. Recently, we reported that IFN-ß activity is affected by interactions with S100A1, S100A4, S100A6, and S100P proteins, which are members of the S100 protein family of multifunctional Ca2+-binding proteins possessing cytokine-like activities (Int J Mol Sci. 2020;21(24):9473). Here we show that IFN-ß interacts with one more representative of the S100 protein family, the S100B protein, involved in numerous oncological and neurological diseases. The use of chemical crosslinking, intrinsic fluorescence, and surface plasmon resonance spectroscopy revealed IFN-ß binding to Ca2+-loaded dimeric and monomeric forms of the S100B protein. Calcium depletion blocks the S100B–IFN-ß interaction. S100B monomerization increases its affinity to IFN-ß by 2.7 orders of magnitude (equilibrium dissociation constant of the complex reaches 47 pM). Crystal violet assay demonstrated that combined application of IFN-ß and S100B (5–25 nM) eliminates their inhibitory effects on MCF-7 cell viability. Bioinformatics analysis showed that the direct modulation of IFN-ß activity by the S100B protein described here could be relevant to progression of multiple oncological and neurological diseases.'

There's a receipt somewhere. If it were my company being ****ged off I would certainly get the lawyers on it.

Not familiar with the laws around this sort of thing in the world of finance, but have to expect if it was someone that was holding a large short or working very hard to load up on the stock, there would be pretty big penalties in play???

its not the front page - its the sponsored content archives.